A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease: The international chronic granulomatous disease cooperative study group

New England Journal of Medicine

Volumn 324, Issue 8, 1991, Pages 509-516

  Gallin, J I ^a   Malech, H L ^a   Weening, R S ^a   Curnutte, J T ^a   Quite, P G ^a   Jaffe, H S ^a   Ezekowitz, R A B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOXACILLIN; GAMMA INTERFERON; PREDNISONE; TRIMETHOPRIM;

ADOLESCENT; ARTICLE; BACTERIAL INFECTION; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PHAGOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; CHILD; DOUBLE-BLIND METHOD; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HUMAN; INFECTION CONTROL; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA, RECOMBINANT; MALE; PHAGOCYTES; PHAGOCYTOSIS; RECURRENCE; STAPHYLOCOCCUS; SUPEROXIDES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0026090433     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199102213240801     Document Type: Article

References (45)

1. Forrest CB, Forehand JR, Axtell RA, Roberts RL, Johnston RB Jr. Clinical features and current management of chronic granulomatous disease. Hematol Oncol Clin North Am 1988; 2: 253-66.
2. Tauber AI, Borregaard N, Simons E, Wright J. Chronic granulomatous disease: a syndrome of phagocyte oxidase deficiencies. Medicine (Baltimore) 1983; 62: 286-309.
3. Curnutte JT, Babior BM. Chronic granulomatous disease. Adv Hum Genet 1987; 16: 229-97.
4. Mills EL, Quie PG. Inheritance of chronic granulomatous disease. In: Gallin JI, Fauci AS, eds. Chronic granulomatous disease. Vol. 3 of Advances in host defense mechanisms. New York: Raven Press, 1983:25–53.
5. Clark RA, Malech HL, Gallin JI, et al. Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. N Engl J Med 1989; 321: 647-52.
6. Baehner RL, Nathan DG. Leukocyte oxidase: defective activity in chronic granulomatous disease. Science 1967; 155: 835-7.
7. Curnutte JT, Whitten DM, Babior BM. Defective superoxide production by granulocytes from patients with chronic granulomatous disease. N Engl J Med 1974; 290: 593-7.
8. Babior BM. The respiratory burst oxidase. Hematol Oncol Clin North Am 1988; 2: 201-12.
9. Curnutte JT, Kipnes RS, Babior BM. Defect in pyridine nucleotide dependent superoxide production by a particulate fraction from the granulocytes of patients with chronic granulomatous disease. N Engl J Med 1975; 293: 628-32.
10. Parkos CA, Allen RA, Cochrane CG, Jesaitis AJ. Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. J Clin Invest 1987; 80: 732-42.
11. Segal AW. Absence of both cytochrome b-245 subunits from neutrophils in X-linked chronic granulomatous disease. Nature 1987; 326: 88-91.
12. Royer-Pokora B. Kunkel LM, Monaco AP, et al. Cloning the gene for an inherited human disorder — chronic granulomatous disease — on the basis of its chromosomal location. Nature 1986; 322: 32-8.
13. Dinauer MC, Orkin SH, Brown R, Jesaitis AJ, Parkos CA. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature 1987; 327: 717-20.
14. Curnutte JT, Berkow RL, Roberts RL, Shurin SB, Scott PJ. Chronic granulomatous disease due to a defect in the cytosolic factor required for nicotinamide adenine dinucleotide phosphate oxidase activation. J Clin Invest 1988; 81: 606-10.
15. Volpp BD, Nauseef WM, Clark RA. Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. Science 1988; 242: 1295-7.
16. Nunoi H, Rotrosen D, Gallin JI, Malech HL. Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science 1988; 242: 1298-1301.
17. Lomax KJ, Leto TL, Nunoi H, Gallin JI, Malech HL. Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science 1989; 245: 409-12.
18. Volpp BD, Nauseef WM, Donelson JE, Moser DR, Clark RA. Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. Proc Natl Acad Sci U S A 1989; 86: 7195-9.
19. Dinauer MC, Pierce EA, Bruns GAP, Curnutte JT, Orkin SH. Human neutrophil cytochrome-b light chain (p22-phox): gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 1990; 86: 1729-37.
20. Curnutte JT, Scott PJ, Mayo LA. Cytosolic components of the respiratory burst oxidase: resolution of four components, two of which are missing in complementing types of chronic granulomatous disease. Proc Natl Acad Sci U S A 1989; 86: 825-9.
21. Leto TL, Lomax KJ, Volpp BD, et al. Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science 1990; 248: 727-30.
22. Nathan CF, Tsunawaki S. Secretion of toxic oxygen products by macrophages: regulatory cytokines and their effects on the oxidase. Ciba Found Symp 1986; 118: 211-30.
23. Berton G, Zeni L, Cassatella MA, Rossi F. Gamma interferon is able to enhance the oxidative metabolism of human neutrophils. Biochem Biophys Res Commun 1986; 138: 1276-82.
24. Guthrie LA, McPhail LC, Henson PH, Johnston RB Jr. Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide: evidence for increased activity of the superoxide-producing enzyme. J Exp Med 1984; 160: 1656-71.
25. Nathan CF, Horowitz CR, de la Harpe J, et al. Administration of recombinant interferon γ to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A 1985; 82: 8686-90.
26. Murray HW. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 1988; 108: 595-608.
27. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-γ in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6-15.
28. Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990; 322: 16-21.
29. Ezekowitz RAB, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 1987; 80: 1009-16.
30. Sechler JMG, Malech HL, White CJ, Gallin JI. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci U S A 1988; 85: 4874-8.
31. Ezekowitz RAB, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319: 146-51.
32. Efron B. Forcing a sequential experiment to be balanced. Biometrika 1971; 58: 403-17.
33. Hannigan JF, Brown BW. Adaptive randomization biased coin-design: experience in a cooperative group clinical trial. Technical report no. 74. Palo Alto, Calif.: Division of Biostatistics, Stanford University, 1982.
34. Babior BM, Cohen HJ. Measurement of neutrophil function: phagocytosis, degranulation, the respiratory burst, and bacterial killing. In: Cline MJ, ed. Leukocyte function. New York: Churchill Livingstone, 1981:1–38.
35. Ezekowitz RAB, Sim RB, MacPherson GG, Gordon S. Interaction of human monocytes, macrophages, and polymorphonuclear leukocytes with zymosan in vitro: role of type 3 complement receptors and macrophage-derived complement. J Clin Invest 1985; 76: 2368-76.
36. Curnutte JT, Babior BM. The effect of bacteria and serum on superoxide production by granulocytes. J Clin Invest 1974; 53: 1662-72.
37. Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley, 1986.
38. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill, 1971.
39. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.
40. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Statist 1982; 10: 1100-20.
41. Fleming TR, Harrington DP. Counting processes and survival analysis. New York: John Wiley (in press).
42. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
43. Dixon WJ, ed. BMDP biomedical computer programs (P-series). Berkeley: University of California Press, 1981.
44. SAS Institute Inc. SAS user's guide: statistics, version 5 edition. Cary, N.C.: SAS Institute, 1985.
45. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.